Genialis, Inc.

Genialis is a precision oncology company that leverages AI and machine learning to develop clinically actionable RNA-based biomarkers. Their core technology, the Genialis Supermodel, is a foundation model trained on large-scale transcriptomic data designed to predict patient response to therapies, elucidate mechanisms of drug resistance, and support drug development and clinical decision-making. The company partners with pharmaceutical and diagnostic firms to optimize clinical trial designs, stratify patient populations, and accelerate the development of precision medicines. By integrating multi-omics data with advanced computational biology, Genialis aims to improve therapeutic outcomes in oncology, particularly in areas like KRAS inhibitors and DNA damage response (DDR) pathways.